Celgene files patent infringement suit against Barr Labs over generic version of ADHD drug Focalin XR®
Clients Celgene Corporation
Jones Day represented Celgene Corporation in a Hatch-Waxman patent infringement action against Barr Laboratories involving Celgene's drug Focalin XR® which is prescribed for the treatment of ADHD. The matter concluded through a mutually agreeable settlement.
Celgene Corporation, et al. v. Barr Laboratories, Inc., Case No. 3-07-cv-05552 (D.N.J.) (Judge Wolfson)